[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,133,676
  • Shares Outstanding, K 166,676
  • Annual Sales, $ 1,476 M
  • Annual Income, $ 241,660 K
  • EBIT $ 204 M
  • EBITDA $ 231 M
  • 60-Month Beta 0.31
  • Price/Sales 4.17
  • Price/Cash Flow 22.07
  • Price/Book 3.51

Options Overview Details

View History
  • Implied Volatility 40.41% (-0.93%)
  • Historical Volatility 34.79%
  • IV Percentile 2%
  • IV Rank 3.64%
  • IV High 112.83% on 07/17/25
  • IV Low 37.67% on 09/09/25
  • Expected Move (DTE 26) 2.47 (6.70%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 120
  • Volume Avg (30-Day) 1,123
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 8,339
  • Open Int (30-Day) 8,526
  • Expected Range 34.34 to 39.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 6
  • High Estimate $0.02
  • Low Estimate $-0.18
  • Prior Year $0.52
  • Growth Rate Est. (year over year) -111.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.83 +12.08%
on 04/27/26
39.56 -6.98%
on 05/13/26
+3.06 (+9.07%)
since 04/22/26
3-Month
27.00 +36.30%
on 03/19/26
39.56 -6.98%
on 05/13/26
+4.89 (+15.32%)
since 02/20/26
52-Week
25.17 +46.23%
on 09/08/25
39.56 -6.98%
on 05/13/26
+6.75 (+22.46%)
since 05/22/25

Most Recent Stories

More News
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

– Real-World Evidence of Positive Impact of LYBALVI ® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder,...

ALKS : 36.80 (-0.41%)
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

– LUMRYZ Met All Primary and Key Secondary Endpoints Demonstrating Statistically Significant and Clinically Meaningful Improvements Compared to Placebo in Excessive Daytime Sleepiness and Patient-Reported...

ALKS : 36.80 (-0.41%)
Alkermes: Q1 Earnings Snapshot

Alkermes: Q1 Earnings Snapshot

ALKS : 36.80 (-0.41%)
Alkermes plc Reports First Quarter 2026 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 ...

ALKS : 36.80 (-0.41%)
Alkermes Reports Tomorrow With Sleep Medicine Acquisition Finally On the Books

Barchart Research What to Expect from ALKS Earnings ALKS Generated May 4, 2026 Current Price $34.17 EPS Estimate $$-0.57 Consensus Rating Moderate Buy Average Move 4.69% Alkermes Reports Tomorrow With...

ALKS : 36.80 (-0.41%)
Alkermes to Report First Quarter Financial Results on May 5, 2026

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company’s first quarter financial results....

ALKS : 36.80 (-0.41%)
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

— Alixorexton Data From Seven-Week Open-Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and Fatigue— ...

ALKS : 36.80 (-0.41%)
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

— 56-Week Post Hoc Analysis Demonstrated Sustained Reduction in Hard-to-Treat Negative Symptoms —

ALKS : 36.80 (-0.41%)
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy...

ALKS : 36.80 (-0.41%)
Alkermes Announces Inaugural Alkermes Pathways APN Research Awardsâ„¢ Program

— Competitive Grant Program to Offer Individual Grants of Up to $10,000 per Project — — Inaugural Application Cycle Open to Licensed Psychiatric-Mental Health Nurse...

ALKS : 36.80 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major...

See More

Key Turning Points

3rd Resistance Point 37.86
2nd Resistance Point 37.56
1st Resistance Point 37.18
Last Price 36.80
1st Support Level 36.50
2nd Support Level 36.20
3rd Support Level 35.82

See More

52-Week High 39.56
Last Price 36.80
Fibonacci 61.8% 34.06
Fibonacci 50% 32.36
Fibonacci 38.2% 30.66
52-Week Low 25.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.